Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Altiratinib - Deciphera Pharmaceuticals

Drug Profile

Altiratinib - Deciphera Pharmaceuticals

Alternative Names: DCC-22701; DCC-2701; DP-5164

Latest Information Update: 28 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Deciphera Pharmaceuticals
  • Class Amides; Antineoplastics; Cyclopropanes; Dicarboxylic acids; Pyridines; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase inhibitors; Proto-oncogene protein c-met inhibitors; TIE 2 receptor antagonists; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Glioblastoma; Solid tumours

Most Recent Events

  • 28 Feb 2020 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Tablet)
  • 28 Feb 2020 No recent reports of development identified for preclinical development in Glioblastoma in USA (PO, Tablet)
  • 30 Jan 2018 Phase-I development is ongoing in Solid-tumours in USA (PO, Tablet)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top